Rebirth for TB vaccine after promising Phase III results
This article was originally published in Scrip
Executive Summary
Immodulon Therapeutics' inactivated whole-cell mycobacterial vaccine provides 39% protection from tuberculosis among HIV-positive patients, show results from a seven-year Phase III trial.